ACEBUTOLOL TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE)

Pieejams no:

SANIS HEALTH INC

ATĶ kods:

C07AB04

SNN (starptautisko nepatentēto nosaukumu):

ACEBUTOLOL

Deva:

200MG

Zāļu forma:

TABLET

Kompozīcija:

ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 200MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100/500

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC BLOCKING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0131282003; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2018-07-16

Produkta apraksts

PRODUCT MONOGRAPH
ACEBUTOLOL
(Acebutolol Hydrochloride)
TABLETS 100, 200 & 400 MG
ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT
Sanis Health Inc.
DATE OF PREPARATION: February 5, 2010
333 Champlain Street, Suite 102
DATE OF REVISION:
Dieppe, New Brunswick
E1A 1P2
Control#: 136306
2
PRODUCT MONOGRAPH
ACEBUTOLOL
(Acebutolol Hydrochloride)
TABLETS 100, 200 AND 400 MG
Antihypertensive and Anti-anginal agent
ACTION AND CLINICAL PHARMACOLOGY
Acebutolol Hydrochloride is a β-adrenergic receptor-blocking agent.
In vitro and in vivo animal
studies show it has a preferential effect on beta
1
adrenoreceptors, chiefly located in cardiac
muscle. This preferential effect is not absolute, however, and at
higher doses, Acebutolol
Hydrochloride inhibits beta
2
adrenoreceptors, chiefly located in the bronchial and vascular
musculature. It possesses some partial agonist activity (or intrinsic
sympathomimetic activity
-
ISA). It is used in the treatment of hypertension and/or prophylaxis
of angina pectoris.
The mechanism of the antihypertensive effect has not been established.
Among the factors that
may be involved are:
a)
competitive ability to antagonize catecholamine-induced tachycardia at
the ~
3
-receptor sites
in the heart, thus decreasing cardiac output;
b)
inhibition of renin release by the kidneys;
c)
inhibition of the vasomotor centres.
3
The mechanism of the anti-anginal effect is also uncertain. An
important factor may be the
reduction of myocardial oxygen requirements by blocking
catecholamine-induced increases in
heart rate, systolic blood pressure, and the velocity and extent of
myocardial contraction.
Acebutolol Hydrochloride is well absorbed from the gastrointestinal
tract. It undergoes extensive
first pass hepatic biotransformation, with an absolute bioavailability
of approximately 40% for
the parent compound. The major metabolite, an N-acetyl derivative
(diacetolol), is
pharmacologically active. This metabolite is equipotent to Acebutolol
Hydrochloride and, in
cats, is more cardioselective than Acebutolol Hydrochloride;